Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00010126
DRKS00010126
Recruiting
N/A

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients - CRISP

AIO-Studien-gGmbH0 sites5,000 target enrollmentJuly 6, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMetastatic Non-small Cell Lung Cancer (NSCLC)C34Malignant neoplasm of bronchus and lung

Overview

Phase
N/A
Intervention
Not specified
Conditions
Metastatic Non-small Cell Lung Cancer (NSCLC)
Sponsor
AIO-Studien-gGmbH
Enrollment
5000
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 6, 2016
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients who meet all of the following criteria are eligible for the project:Histologically confirmed non\-small cell lung cancer (NSCLC)
  • •2\. Informed consent no later than four weeks after start of first\-line treatment
  • •3\. Age \= 18 years
  • •4\. Able to understand and willing to sign written Informed Consent and to complete patient\-reported\-outcome assessment instruments
  • •5\. Main project:
  • •\- Stage IV, IIIC or stage IIIB (UICC8\) if patient is ineligible for curative surgery and/or radiochemotherapy
  • •\- Systemic therapy
  • •In the main project it is strongly recommended that patients’ tumor samples are tested for EGFR mutation in exons 18\-21, ALK rearrangement and ROS1 rearrangement as well as PD\-L1 expression by a certified laboratory before the start of first\-line treatment.
  • •6\. Satellite Stage II/III:
  • •\- Stage II, stage IIIA or stage IIIB (UICC8\) if patient is eligible for curative surgery and/or radiochemotherapy

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
N/A
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma PatientsMetastatic Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IINon Small Cell Lung Cancer Stage IIISmall-cell Lung CancerNon-small Cell Lung Cancer Stage I
NCT02622581AIO-Studien-gGmbH12,400
Unknown
N/A
Molecular Diagnostic Platform for AMLAcute Myeloid Leukemia (AML)
NCT04446741PETHEMA Foundation2,000
Recruiting
N/A
Myeloma Registry Platform (MYRIAM)Multiple Myeloma
NCT03308474iOMEDICO AG2,200
Recruiting
N/A
The low platelet blood studyThrombocytopeniaHaematological Disorders
ISRCTN95606674niversity of Bristol100
Recruiting
N/A
molecular based analysis and novel therapies development of chronic myelocytic leukemiachronic myelocytic leukemia
JPRN-UMIN000015409Keio University School of Medicine, Division of Hematology200